Your browser doesn't support javascript.
loading
[Clinical characteristics of 272 437 patients with different histopathological subtypes of primary esophageal malignant tumors].
Wang, L D; Li, X; Song, X K; Zhao, F Y; Zhou, R H; Xu, Z C; Liu, A L; Li, J L; Li, X Z; Wang, L G; Zhang, F H; Zhu, X M; Li, W X; Zhao, G Z; Guo, W W; Gao, X M; Li, L X; Wan, J W; Ku, Q X; Xu, F G; Zhu, A F; Ji, H X; Li, Y L; Ren, S L; Zhou, P N; Chen, Q D; Bao, S G; Gao, H J; Yang, J C; Wei, W M; Mao, Z Z; Han, Z W; Chang, Y F; Zhou, X N; Han, W L; Han, L L; Lei, Z M; Fan, R; Wang, Y Z; Yang, J J; Ji, Y; Chen, Z J; Li, Y F; Hu, L; Sun, Y J; Chen, G L; Bai, D; You, Duo.
Afiliação
  • Wang LD; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
  • Li X; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Zhengzhou Univer
  • Song XK; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
  • Zhao FY; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
  • Zhou RH; Department of Thoracic Surgery, Anyang Tumor Hospital, Anyang 455000, China.
  • Xu ZC; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
  • Liu AL; Department of Oncology, Linzhou Tumor Hospital, Linzhou 456550, China.
  • Li JL; Department of Oncology, Linzhou Tumor Hospital, Linzhou 456550, China.
  • Li XZ; Department of Pathology, Linzhou Esophageal Cancer Hospital, Linzhou 456592, China.
  • Wang LG; Department of Oncology, Linzhou People's Hospital, Linzhou 456550, China.
  • Zhang FH; Department of Thoracic Surgery, Xinxiang Central Hospital, Xinxiang 453000, China.
  • Zhu XM; Department of Pathology, Xinxiang Central Hospital, Xinxiang 453000, China.
  • Li WX; Department of Pathology, Cixian People's Hospital, Handan 056599, China.
  • Zhao GZ; Department of Pathology, the First Affiliated Hospital of Xinxiang Medicine University, Xinxiang 453100, China.
  • Guo WW; Department of Oncology, Linzhou Tumor Hospital, Linzhou 456550, China.
  • Gao XM; Department of Oncology, Linzhou People's Hospital, Linzhou 456550, China.
  • Li LX; Xinxiang Key Laboratory for Molecular Therapy of Cancer, Xinxiang Medical University, Xinxiang 453003, China.
  • Wan JW; Department of Oncology, Nanyang Central Hospital, Nanyang 473009, China.
  • Ku QX; Department of Endoscopy, the Second Affiliated Hospital of Nanyang Medical College, Nanyang 473000, China.
  • Xu FG; Department of Oncology, the First People's Hospital of Nanyang, Nanyang 473002, China.
  • Zhu AF; Department of Oncology, the First People's Hospital of Shangqiu, Shangqiu 476000, China.
  • Ji HX; Department of Clinical Laboratory, the Affiliated Heping Hospital of Changzhi Medical College, Changzhi 046000, China.
  • Li YL; Department of Pathology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450003, China.
  • Ren SL; Department of Pathology, the Second Affiliated Hospital, Zhengzhou University, Zhengzhou 450003, China.
  • Zhou PN; Department of Pathology, Henan People's Hospital, Zhengzhou 450003, China.
  • Chen QD; Department of Thoracic Surgery, Henan Tumor Hospital, Zhengzhou 450003, China.
  • Bao SG; Department of Oncology, Anyang District Hospital, Anyang 455002, China.
  • Gao HJ; Department of Oncology, the First Affiliated Hospital, Henan University of Science and Technology, Luoyang 471003, China.
  • Yang JC; Department of Pathology, Anyang Tumor Hospital, Anyang 455000, China.
  • Wei WM; Department of Thoracic Surgery, Linzhou Esophageal Cancer Hospital, Linzhou 456592, China.
  • Mao ZZ; Department of Thoracic Surgery, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou 310005, China.
  • Han ZW; Department of Pathology, Zhenping County People's Hospital, Nanyang 474250, China.
  • Chang YF; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
  • Zhou XN; Department of Gastroenterology, the Second Affiliated Hospital, Zhengzhou University, Zhengzhou 450003, China.
  • Han WL; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
  • Han LL; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
  • Lei ZM; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
  • Fan R; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
  • Wang YZ; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
  • Yang JJ; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
  • Ji Y; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
  • Chen ZJ; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
  • Li YF; Department of Gastroenterology, the Third People's Hospital of Huixian, Huixian 453600, China.
  • Hu L; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
  • Sun YJ; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Zhengzhou Univer
  • Chen GL; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Zhengzhou Univer
  • Bai D; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
  • You D; State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Zhonghua Nei Ke Za Zhi ; 61(9): 1023-1030, 2022 Sep 01.
Article em Zh | MEDLINE | ID: mdl-36008295
ABSTRACT

Objective:

To characterize the histopathological subtypes and their clinicopathological parameters of gender and onset age by common, rare and sparse primary esophageal malignant tumors (PEMT).

Methods:

A total of 272 437 patients with PEMT were enrolled in this study, and all of the patients were received radical surgery. The clinicopathological information of the patients was obtained from the database established by the State Key Laboratory of Esophageal Cancer Prevention & Treatment from September 1973 to December 2020, which included the clinical treatment, pathological diagnosis and follow-up information of esophagus and gastric cardia cancers. All patients were diagnosed and classified by the criteria of esophageal tumor histopathological diagnosis and classification (2019) of the World Health Organization (WHO). The esophageal tumors, which were not included in the WHO classification, were analyzed separately according to the postoperative pathological diagnosis. The χ2 test was performed by the SPSS 25.0 software on count data, and the test standard α=0.05.

Results:

A total of 32 histopathological types were identified in the enrolled PEMT patients, of which 10 subtypes were not included in the WHO classification. According to the frequency, PEMT were divided into common (esophageal squamous cell carcinoma, ESCC, accounting for 97.1%), rare (esophageal adenocarcinoma, EAC, accounting for 2.3%) and sparse (mainly esophageal small cell carcinoma, malignant melanoma, etc., accounting for 0.6%). All the common, rare, and sparse types occurred predominantly in male patients, and the gender difference of rare type was most significant (EAC, male∶ female, 2.67∶1), followed with common type (ESCC, male∶ female, 1.78∶1) and sparse type (male∶ female, 1.71∶1). The common type (ESCC) mainly occurred in the middle thoracic segment (65.2%), while the rare type (EAC) mainly occurred in the lower thoracic segment (56.8%). Among the sparse type, malignant melanoma and malignant fibrous histiocytoma were both predominantly located in the lower thoracic segment (51.7%, 66.7%), and the others were mainly in the middle thoracic segment.

Conclusion:

ESCC is the most common type among the 32 histopathological types of PEMT, followed by EAC as the rare type, and esophageal small cell carcinoma and malignant melanoma as the major sparse type, and all of which are mainly occur in male patients. The common type of ESCC mainly occur in the middle thoracic segment, while the rare type of EAC mainly in the lower thoracic segment. The mainly sparse type of malignant melanoma and malignant fibrous histiocytoma predominately occur in the lower thoracic segment, and the remaining sparse types mainly occur in the middle thoracic segment.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Carcinoma de Células Pequenas / Histiocitoma Fibroso Maligno / Carcinoma de Células Escamosas do Esôfago / Melanoma Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: Zh Revista: Zhonghua Nei Ke Za Zhi Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Carcinoma de Células Pequenas / Histiocitoma Fibroso Maligno / Carcinoma de Células Escamosas do Esôfago / Melanoma Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: Zh Revista: Zhonghua Nei Ke Za Zhi Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China